摘要
胃癌在全球的发病率逐年上升,小分子靶向药物与免疫检查点抑制剂的发展为晚期胃癌患者带来了希望,然而关于治疗中联合用药的药学监护点以及相关不良反应的发现和解决,暂未见相关的研究报道。本文临床药师参与1例晚期转移性胃癌患者免疫检查点抑制剂联合化学治疗加小分子靶向药物联合应用,根据患者的实际情况对化疗方案以及靶向药物的选择,使用剂量进行个体化建议,并且对患者进行全程药学监护,保障患者的用药安全。
The incidence of gastric cancer is increasing globally every year.The development of small molecule targeted drugs and immunocheckpoint inhibitors have provided new therapeutic methods for patients with advanced gastric cancer.Regretfully,there is no relevant study about the key points of pharmaceutical care in the combined treatment as well as the discovery and solution of adverse drug reactions.In this paper,clinical pharmacist studied a patient with advanced metastatic gastric cancer,for whom applied immunocheckpoint inhibitor combined with chemotherapy and small molecule targeted therapy were used.The clinical pharmacist proposed the chemotherapy and selection of small molecule targeted drugs according to the situation of the patient,as well as individualized drug dosage.Process of pharmaceutical care was provided by clinical pharmacists to ensure the safety of drug use and patient.
作者
沈晓
汪新茹
陈明
汪硕闻
SHEN Xiao;WANG Xin-ru;CHEN Ming;WANG Shuo-wen(Department of Clinical Pharmacy,Shanghai General Hospital,Shanghai Jiao Tong University,Shanghai 200080;Suzhou Kowloon Hospital,Shanghai Jiao Tong University,Suzhou Jiangsu 215028;The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052)
出处
《中南药学》
CAS
2020年第7期1215-1218,共4页
Central South Pharmacy
基金
上海交通大学医学院转化医学协同创新中心合作研究项目(No.TM201607)
上海市卫计委重要薄弱学科建设——临床药学(No.2016ZB0302)。
关键词
胃癌
化学治疗
小分子靶向药物
免疫检查点抑制剂
药学监护
gastric cancer
chemotherapy
small molecule targeted drug
immunocheckpoint inhibitor
pharmaceutical care
